Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,627 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,360 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00880009 | Study Evaluating Bosutinib-Letrozole Combination Versus Letrozole Alone In Post Menopausal Women With Breast Cancer | terminated | Phase 2 | 16 | PfizerINDUSTRY | 7 | Sep 27, 2021 | clinicaltrials |
| NCT03894007 | Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer(PREDIXIIHER2) | terminated | Phase 2 | 6 | Renske AltenaOTHER | 1 | Sep 23, 2021 | clinicaltrials |
| NCT02984683 | Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer | terminated | Phase 2 | 23 | SanofiINDUSTRY | 5 | Sep 8, 2021 | clinicaltrials |
| NCT03795012 | Trial With Eribulin or Eribulin+ Endocrine Therapy in Locally-recurrent or Metastatic Breast Cancer Patients | terminated | Phase 2 | 22 | MedSIROTHER | 1 | Aug 31, 2021 | clinicaltrials |
| NCT03186937 | A Window of Opportunity Study of Methionine Deprivation in Triple Negative Breast Cancer | terminated | Phase 2 | 6 | University of Wisconsin, MadisonOTHER | 1 | Aug 18, 2021 | clinicaltrials |
| NCT03566485 | Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer | terminated | Phase 1 / Phase 2 | 12 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Aug 11, 2021 | clinicaltrials |
| NCT01988090 | High Dose Vitamin D vs Standard Dose Vitamin D Study | terminated | Phase 2 | 93 | Mothaffar RimawiOTHER | 1 | Aug 9, 2021 | clinicaltrials |
| NCT03858972 | Tesetaxel Plus Reduced Dose of Capecitabine in Patients With HER2 Negative, HR Positive, LA/MBC(CONTESSA 2) | terminated | Phase 2 | 152 | Odonate Therapeutics, Inc.INDUSTRY | 6 | Jul 30, 2021 | clinicaltrials |
| NCT03952325 | Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBC(CONTESSA TRIO) | terminated | Phase 2 | 294 | Odonate Therapeutics, Inc.INDUSTRY | 3 | Jul 30, 2021 | clinicaltrials |
| NCT01823835 | A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer | terminated | Phase 1 / Phase 2 | 152 | Genentech, Inc.INDUSTRY | 4 | Jun 18, 2021 | clinicaltrials |
| NCT00542191 | Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer | terminated | Phase 2 | 30 | Leo W. Jenkins Cancer CenterOTHER | 1 | May 26, 2021 | clinicaltrials |
| NCT03983395 | Study of ISB 1302 (CD3 Bispecific Ab) in HER2-positive Metastatic Breast Cancer | terminated | Phase 1 / Phase 2 | 1 | Ichnos Sciences SAINDUSTRY | 1 | May 24, 2021 | clinicaltrials |
| NCT01861054 | Pilot Study to Evaluate Safety & Biological Effects of Orally Administered Reparixin in Early Breast Cancer | terminated | Phase 2 | 20 | Dompé Farmaceutici S.p.AINDUSTRY | 1 | May 14, 2021 | clinicaltrials |
| NCT03051672 | Phase II PEMBROLIZUMAB + PALLIATIVE RADIOTHERAPY IN BC | terminated | Phase 2 | 8 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 27, 2021 | clinicaltrials |
| NCT02569801 | A Study of GDC-0810 Versus Fulvestrant in Postmenopausal Women With Advanced or Metastatic Breast Cancer Resistant to Aromatase Inhibitor (AI) Therapy(HydranGea) | terminated | Phase 2 | 71 | Genentech, Inc.INDUSTRY | 6 | Apr 23, 2021 | clinicaltrials |
| NCT00461773 | Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer | terminated | Phase 2 | 5 | Yale UniversityOTHER | 1 | Mar 16, 2021 | clinicaltrials |
| NCT00470249 | Carboplatin and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Breast Cancer | terminated | Phase 2 | 5 | University of SouthamptonOTHER | 1 | Feb 1, 2021 | clinicaltrials |
| NCT02362230 | Evaluation of Icotinib in Metastatic Triple-negative Breast Cancer After Second-line Therapy | terminated | Phase 2 | 26 | Sun Yat-sen UniversityOTHER | 1 | Jan 29, 2021 | clinicaltrials |
| NCT03244358 | Evaluation of Epalrestat in Metastatic Triple-negative Breast Cancer | terminated | Phase 2 | 12 | Sun Yat-sen UniversityOTHER | 1 | Jan 29, 2021 | clinicaltrials |
| NCT00090844 | Triptorelin for Preserving Ovarian Function in Premenopausal Women Receiving Chemotherapy for Early-Stage Breast Cancer | terminated | Phase 2 | 49 | University of South FloridaOTHER | 1 | Jan 28, 2021 | clinicaltrials |
| NCT00448266 | Intensified IAA With PBPC Support in Breast Tumors With Evidence of a HRD | terminated | Phase 2 / Phase 3 | 12 | The Netherlands Cancer InstituteOTHER | 1 | Jan 22, 2021 | clinicaltrials |
| NCT01702558 | A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (mBC) or HER2-Positive Locally Advanced/Metastatic Gastric Cancer (LA/mGC)(TRAXHER2) | terminated | Phase 2 | 182 | Hoffmann-La RocheINDUSTRY | 12 | Jan 22, 2021 | clinicaltrials |
| NCT02677714 | 99mTc-rhAnnexin V-128 Imaging and Cardiotoxicity in Patients With Early Breast Cancer | terminated | Phase 2 | 14 | Advanced Accelerator ApplicationsINDUSTRY | 1 | Dec 11, 2020 | clinicaltrials |
| NCT01495247 | Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer | terminated | Phase 1 / Phase 2 | 18 | Novartis PharmaceuticalsINDUSTRY | 2 | Dec 8, 2020 | clinicaltrials |
| NCT02993094 | Ixazomib (MLN9708) in Combination With Carboplatin in Pretreated Women With Advanced Triple Negative Breast Cancer | terminated | Phase 1 / Phase 2 | 31 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 1 | Nov 30, 2020 | clinicaltrials |
| NCT02368691 | Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC) | terminated | Phase 2 | 32 | GTxINDUSTRY | 1 | Nov 18, 2020 | clinicaltrials |
| NCT00796107 | A Study of R1507 in Combination With Letrozole in Postmenopausal Women With Advanced Breast Cancer | terminated | Phase 2 | 6 | Hoffmann-La RocheINDUSTRY | 1 | Nov 13, 2020 | clinicaltrials |
| NCT01745367 | Tivozanib in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer(BATON-BC) | terminated | Phase 2 | 30 | AVEO Pharmaceuticals, Inc.INDUSTRY | 10 | Oct 27, 2020 | clinicaltrials |
| NCT03724253 | [68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin Releasing Peptide Receptor (GRPR)(NeoFIND) | terminated | Phase 2 | 19 | Advanced Accelerator ApplicationsINDUSTRY | 2 | Oct 23, 2020 | clinicaltrials |
| NCT00138125 | Fulvestrant and/or Trastuzumab as First-Line Therapy in Treating Postmenopausal Women With Stage IV Breast Cancer | terminated | Phase 2 | 2 | Translational Oncology Research InternationalOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT00622466 | Sorafenib and Paclitaxel in Treating Patients With Metastatic Breast Cancer | terminated | Phase 2 | 20 | University of Texas Southwestern Medical CenterOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT00751101 | Nicotine Patches in Reducing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine For Metastatic Breast Cancer | terminated | Phase 2 | 24 | University of California, San FranciscoOTHER | 1 | Oct 5, 2020 | clinicaltrials |
| NCT00536939 | Trial of Paclitaxel, Bevacizumab, and Enzastaurin Versus Paclitaxel, Bevacizumab and Placebo for Breast Cancer | terminated | Phase 2 | 2 | Eli Lilly and CompanyINDUSTRY | 1 | Sep 24, 2020 | clinicaltrials |
| NCT01697293 | PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer | terminated | Phase 1 / Phase 2 | 34 | Prescient Therapeutics, Ltd.INDUSTRY | 1 | Sep 24, 2020 | clinicaltrials |
| NCT00780676 | Personalized Treatment Selection for Metastatic Breast Cancer | terminated | Phase 2 | 97 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 3, 2020 | clinicaltrials |
| NCT03241810 | Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer(SHERBOC) | terminated | Phase 2 | 22 | Elevation OncologyINDUSTRY | 6 | Sep 2, 2020 | clinicaltrials |
| NCT03430466 | Anti PD-L1 Antibody + Anti CTLA-4 Antibody in Combination With Hormone Therapy in Patients With Hormone Receptor Positive HER2-negative Recurrent or Metastatic Breast Cancer | terminated | Phase 2 | 1 | Kyoto Breast Cancer Research NetworkOTHER | 1 | Aug 12, 2020 | clinicaltrials |
| NCT01225172 | Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors | terminated | Phase 2 | 77 | Bristol-Myers SquibbINDUSTRY | 1 | Aug 11, 2020 | clinicaltrials |
| NCT00437294 | Enzastaurin in Combination of Capecitabine to Treat Breast Cancer | terminated | Phase 2 | 86 | Eli Lilly and CompanyINDUSTRY | 5 | Aug 10, 2020 | clinicaltrials |
| NCT00112749 | Infliximab in Treating Cancer-Related Fatigue in Postmenopausal Women Who Have Undergone Treatment for Breast Cancer | terminated | Phase 2 | 7 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 31, 2020 | clinicaltrials |
| NCT02685111 | Intermittent G-CSF in Patients With Breast Cancer Receiving Adjuvant Docetaxel, Doxorubicin, and Cyclophosphamide (TAC) | terminated | Phase 2 | 22 | Asan Medical CenterOTHER | 1 | Jul 31, 2020 | clinicaltrials |
| NCT00905021 | Exemestane With Sunitinib (SUTENT®) in Metastatic Breast Cancer(EXTENT) | terminated | Phase 1 / Phase 2 | 4 | Baylor Breast Care CenterOTHER | 1 | Jul 24, 2020 | clinicaltrials |
| NCT02892734 | Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer | terminated | Phase 2 | 3 | Northwestern UniversityOTHER | 1 | Jul 16, 2020 | clinicaltrials |
| NCT00003086 | Repeated Bone Marrow Transplantation in Treating Women With Advanced Breast Cancer | terminated | Phase 1 / Phase 2 | 12 | Louisiana State University Health Sciences Center ShreveportOTHER | 1 | Jul 14, 2020 | clinicaltrials |
| NCT02624700 | 2nd Line Treatment With Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer | terminated | Phase 2 | 13 | Virginia Commonwealth UniversityOTHER | 1 | Jul 14, 2020 | clinicaltrials |
| NCT02462200 | Shave Margins in Breast Conservation Therapy(SMART) | terminated | Phase 2 | 81 | Washington University School of MedicineOTHER | 1 | Jun 25, 2020 | clinicaltrials |
| NCT02202746 | A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer | terminated | Phase 2 | 178 | Clovis Oncology, Inc.INDUSTRY | 1 | Jun 23, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Sep 27, 2021source: clinicaltrials